1. Home
  2. NMRA vs TRDA Comparison

NMRA vs TRDA Comparison

Compare NMRA & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • TRDA
  • Stock Information
  • Founded
  • NMRA 2019
  • TRDA 2016
  • Country
  • NMRA United States
  • TRDA United States
  • Employees
  • NMRA N/A
  • TRDA N/A
  • Industry
  • NMRA
  • TRDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NMRA
  • TRDA Health Care
  • Exchange
  • NMRA Nasdaq
  • TRDA Nasdaq
  • Market Cap
  • NMRA 268.5M
  • TRDA 233.5M
  • IPO Year
  • NMRA 2023
  • TRDA 2021
  • Fundamental
  • Price
  • NMRA $1.62
  • TRDA $5.28
  • Analyst Decision
  • NMRA Buy
  • TRDA Strong Buy
  • Analyst Count
  • NMRA 8
  • TRDA 3
  • Target Price
  • NMRA $7.14
  • TRDA $25.67
  • AVG Volume (30 Days)
  • NMRA 383.3K
  • TRDA 231.6K
  • Earning Date
  • NMRA 11-11-2025
  • TRDA 11-04-2025
  • Dividend Yield
  • NMRA N/A
  • TRDA N/A
  • EPS Growth
  • NMRA N/A
  • TRDA N/A
  • EPS
  • NMRA N/A
  • TRDA N/A
  • Revenue
  • NMRA N/A
  • TRDA $79,476,000.00
  • Revenue This Year
  • NMRA N/A
  • TRDA N/A
  • Revenue Next Year
  • NMRA N/A
  • TRDA N/A
  • P/E Ratio
  • NMRA N/A
  • TRDA N/A
  • Revenue Growth
  • NMRA N/A
  • TRDA N/A
  • 52 Week Low
  • NMRA $0.61
  • TRDA $4.93
  • 52 Week High
  • NMRA $17.19
  • TRDA $21.79
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 47.71
  • TRDA 42.86
  • Support Level
  • NMRA $1.60
  • TRDA $5.08
  • Resistance Level
  • NMRA $1.70
  • TRDA $5.53
  • Average True Range (ATR)
  • NMRA 0.09
  • TRDA 0.26
  • MACD
  • NMRA -0.01
  • TRDA 0.02
  • Stochastic Oscillator
  • NMRA 8.51
  • TRDA 18.87

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Share on Social Networks: